Guilbot Angèle, Bangratz Marie, Ait Abdellah Samira, Lucas Christian
Pileje Laboratoire, 37 quai de Grenelle, 75015, 15, Paris cedex, France.
Centre d'Evaluation et de Traitement de la Douleur, service de neurochirurgie, Hôpital Salengro, CHRU de Lille, 59037, Lille Cedex, France.
BMC Complement Altern Med. 2017 Aug 30;17(1):433. doi: 10.1186/s12906-017-1933-7.
BACKGROUND: Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study. METHODS: Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months. RESULTS: Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated. CONCLUSIONS: Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.
背景：小白菊（小白菊）、镁和辅酶Q10常用于偏头痛预防。在一项观察性研究中对这三种药物的固定组合（Antemig®，PiLeJe）进行了补充研究。 方法：根据国际头痛协会标准患有偏头痛的成年患者由全科医生招募（前一个月内≥2次偏头痛发作；排除慢性偏头痛和药物过度使用），在为期一个月的基线期后，每天补充一片含100毫克小白菊、100毫克辅酶Q10和112.5毫克镁的药物，持续3个月。 结果：与基线期相比，补充药物在补充的第三个月显著减少了偏头痛头痛的天数（1.3天±1.5天对4.9天±2.6天，p<0.0001；n = 68例意向性分析；主要标准）。减少在补充期间是渐进的，从第一个月就显著（第一个月：-2.5天±3.1天，p<0.0001；第二个月：-3天±2.8天，p<0.0001）。偏头痛头痛天数减少至少50%的患者比例在3个月后为75%（51/68），在补充期间逐渐增加（1个月后为63.2%[43/68]，2个月后为70.6%[48/68]）。焦虑和抑郁症状患者的比例（医院焦虑和抑郁量表）在基线期和补充的第三个月之间，抑郁从61.9%（39/63例有可用信息的患者）降至35%（21/60）；焦虑从52.4%（33/63）降至30%（18/60）。还观察到生活质量（生活质量与偏头痛问卷）有所改善。该组合耐受性良好。 结论：结果表明，所评估的含小白菊、辅酶Q10和镁的专利补充剂对成年患者预防偏头痛可能有益且安全，值得进一步研究。 试验注册：ClinicalTrials.gov：NCT02901756，于2016年8月24日进行回顾性注册。
BMC Complement Altern Med. 2017-8-30
Neurol Sci. 2017-5
Neurol Sci. 2017-5
Antioxidants (Basel). 2025-3-6
Prim Health Care Res Dev. 2025-2-14
Curr Pain Headache Rep. 2025-1-24
J Headache Pain. 2024-10-31
Curr Pain Headache Rep. 2022-3
Physiol Res. 2021-12-30
Curr Treat Options Neurol. 2016-4
Cochrane Database Syst Rev. 2015-4-20
Semin Pediatr Neurol. 2013-9
Zotero 插件